EHE | Jotup

EHE Health Completes Study Citing Prevention as Source of Lower Healthcare Costs

Retrieved on:

星期四, 四月 11, 2024

NEW YORK, April 11, 2024 /PRNewswire/ -- EHE Health is excited to share results from a two-year analysis demonstrating the power of comprehensive preventive care. The study shows that engagement with EHE Health achieves 14% reduction in total cost of care, 26% reduction in emergency room utilization, and >35% fewer inpatient admissions. The analysis was conducted for multiple national employers to measure the impact of comprehensive preventive exams, and how they affect healthcare costs, utilization, and overall quality.

Key Points:

NEW YORK, April 11, 2024 /PRNewswire/ -- EHE Health is excited to share results from a two-year analysis demonstrating the power of comprehensive preventive care.
The study shows that engagement with EHE Health achieves 14% reduction in total cost of care, 26% reduction in emergency room utilization, and >35% fewer inpatient admissions.
The study, which analyzed working age adults (ages 25 through 64 years old), was designed to compare the health status, engagement, and health outcomes of EHE Health users to non-users.
"At EHE, we are constantly asked by prospective clients how EHE Health can save them money," he said.

Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on:

星期二, 三月 12, 2024

ODD, Research, NF2, RAF, RAS, Patient, Acquisition, Mesothelioma, Drug development, EHE, FDA, Food, Pharmaceutical industry

BOSTON, March 12, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the fourth quarter and full year ending December 31, 2023. The Company also provided an update across the organization and pipeline.

Key Points:

Closed 2023 in a strong financial position with $175M; runway into 2H 2026
BOSTON, March 12, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the fourth quarter and full year ending December 31, 2023.
Collaboration revenue for the three and twelve months ended December 31, 2023 was $0.7 million and $9.2 million, respectively.
Research and development expenses for the three and twelve months ended December 31, 2023 were $14.3 million and $59.7 million, respectively.
General and administrative for the three and twelve months ended December 31, 2023 were $8.3 million and $24.9 million, respectively.

Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results

Retrieved on:

星期四, 十一月 9, 2023

BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the quarter ended September 30, 2023, and provided a corporate update. The Company also shared initial data from twenty-six (26) patients treated in the ongoing dose escalation portion of the Phase I clinical trial of IK-930, a novel, oral, potent, and highly selective Hippo pathway inhibitor.

Key Points:

The Company also shared initial data from twenty-six (26) patients treated in the ongoing dose escalation portion of the Phase I clinical trial of IK-930, a novel, oral, potent, and highly selective Hippo pathway inhibitor.
“This early look at the IK-930 dose escalation data strongly supports our differentiated approach to targeting the Hippo pathway.
Importantly, following the target biology and initially focusing on EHE has allowed us to observe clinical activity of IK-930 early in our dose escalation.
Twenty-six patients with a range of solid tumors were treated in the dose escalation portion of the study as of October 31, 2023.

Nectar Life Sciences, the Health Technology Company Behind the First Hybrid, Vertically-Integrated Allergy Care Platform, Opens First Nectar Allergy Center in New York City

Retrieved on:

星期一, 八月 28, 2023

Nectar Life Sciences , the trusted health technology company behind the first hybrid, vertically-integrated allergy care platform, today announced the grand opening of its flagship Nectar Allergy Center , located in New York City.

Key Points:

Nectar Life Sciences , the trusted health technology company behind the first hybrid, vertically-integrated allergy care platform, today announced the grand opening of its flagship Nectar Allergy Center , located in New York City.
Nectar’s care offerings are now expanding from environmental allergies to more complex allergic conditions, including asthma, food allergies, and eczema.
Dr. Akansha Ganju, M.D., has also joined the company as Medical Director of the Nectar Allergy Center.
Increasing accessibility to comprehensive allergy care is a core part of Nectar Life Sciences’s mission, so the Allergy Center is strategically located near many subway and bus stops.

Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting

Retrieved on:

星期一, 四月 17, 2023

BOSTON, April 17, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that it will present preclinical data in two poster presentations highlighting the Company’s novel Hippo pathway inhibitor, IK-930, at the American Association for Cancer Research (AACR) Annual Meeting taking place in Orlando, FL from April 14-19, 2023.

Key Points:

Data being shared today reveals that IK-930 selectively binds and inhibits TEAD1 and further describes the mechanism for its antitumor activity.
Key advantages demonstrated in the nonclinical studies include IK-930’s superior tolerability and comparable antitumor activity compared to panTEAD inhibition, resulting in a significantly improved projected therapeutic window in cancer patients.
IK-930 was designed as a TEAD1-selective inhibitor to avoid on-target renal toxicity expected from panTEAD inhibition.
TEAD1 is the most highly expressed TEAD paralog in mesothelioma and epithelioid hemangioendothelioma (EHE).

Collaborative Research Promotes Thomas Rodriguez-Schucker to President

Retrieved on:

星期三, 三月 1, 2023

HIV, Person, Cyber Security Collaborative Research Alliance, News, White, Senior, Public, EHE, Ryan White, HIV/AIDS denialism, Eastern Virginia Medical School, Person to Person: Live at the Blue Note, STI, Pharmaceutical industry

AUSTIN, Texas, March 1, 2023 /PRNewswire/ -- Collaborative Research, a strategic planning health care firm supporting local public health, social-service and community-based organizations for the past 20 years, today announced the appointment of Thomas Rodriguez-Schucker to President. The news comes as Founder and CEO Jeff Daniel steps away to focus on the launch of the Collaborative Research Foundation, a new 501c3 non-profit that will roll out in Q4 of 2023.

Key Points:

AUSTIN, Texas, March 1, 2023 /PRNewswire/ -- Collaborative Research , a strategic planning health care firm supporting local public health, social-service and community-based organizations for the past 20 years, today announced the appointment of Thomas Rodriguez-Schucker to President.
The news comes as Founder and CEO Jeff Daniel steps away to focus on the launch of the Collaborative Research Foundation, a new 501c3 non-profit that will roll out in Q4 of 2023.
"As we continue the hard work of bringing an End to the HIV Epidemic, there is no better leader than Thomas to drive Collaborative Research's continued focus on that mission.
"It's all the more exciting as Jeff moves forward with the Collaborative Research Foundation, which will raise the bar for delivering exceptional prevention and care on a national level and will further our collective mission to End the HIV Epidemic."

Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Retrieved on:

星期一, 十一月 7, 2022

BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the third quarter ended September 30, 2022. The Company also shared updates across its pipeline, including highlighting the data from the Society for Immunotherapy of Cancer Conference (SITC) abstract released this morning from the IK-175 clinical program in urothelial carcinoma.

Key Points:

It has been an extremely productive time for us in our targeted oncology efforts as well, with our RAS pathway development candidate coming shortly, and advancing our TEAD program.
Research and development expenses were $18.9 million and $13.4 million for the three months ended September 30, 2022 and 2021, respectively.
General and administrative expenses were $5.4 million and $4.9 million for the three months ended September 30, 2022 and 2021, respectively.
Ikena Oncologyis focused on developing novel therapies targeting key signaling pathways that drive the formation and spread of cancer.

Ikena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic Resistance

Retrieved on:

星期三, 十月 26, 2022

These data reinforce our belief that the Hippo pathway is often activated as a critical resistance mechanism to other targeted therapies, and that IK-930 has the potential to overcome therapeutic resistance, said Jeffrey Ecsedy, Ph.D., Chief Development Officer of Ikena.

Key Points:

These data reinforce our belief that the Hippo pathway is often activated as a critical resistance mechanism to other targeted therapies, and that IK-930 has the potential to overcome therapeutic resistance, said Jeffrey Ecsedy, Ph.D., Chief Development Officer of Ikena.
Multiple combination cohorts are planned, the first of which will be assessing IK-930s impact on resistance to EGFR inhibitors.
Ikena is advancing IK-930 both as a monotherapy in patients with Hippo pathway mutated cancers and in combination with other approved targeted therapies to combat therapeutic resistance.
Ikena Oncologyis focused on developing novel therapies targeting key signaling pathways that drive the formation and spread of cancer.

Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway

Retrieved on:

星期二, 十月 18, 2022

BOSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today provided a research & development update on the Company’s lead targeted oncology program in TEAD inhibition. Ikena also announced a clinical trial collaboration agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for the evaluation of TAGRISSO® (osimertinib), a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in combination with Ikena’s IK-930 as treatment for patients with EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).

Key Points:

The ongoing IK-930 clinical trial has planned cohorts exploring combinations with targeted therapies in which treatment-induced activation of the Hippo pathway may drive resistance.
Ikena OncologyTM is focused on developing novel therapies targeting key signaling pathways that drive the formation and spread of cancer.
The Companys lead targeted oncology program, IK-930, is a TEAD inhibitor addressing the Hippo signaling pathway, a known tumor suppressor pathway that also drives resistance to multiple targeted therapies.
The Companys ongoing discovery research spans other targets in the Hippo pathway as well as the RAS signaling pathway.

EHE Health Partners with Danone North America, Underscoring Danone's Ongoing Commitment to Employee Health and Wellbeing

Retrieved on:

星期二, 八月 30, 2022

NEW YORK and BROOMFIELD, Colo., Aug. 30, 2022 /PRNewswire/ -- Today, EHE Health, a national healthcare provider, and Danone North America, the purpose-driven food and beverage leader with a diverse portfolio of dairy and plant-based brands, announced a new three-year relationship to facilitate prevention at scale and drive better health outcomes for Danone's U.S.-based workforce. As one of the world's largest Certified B Corporations®, Danone is guided by its responsibility to use its business as a force for good, which includes its efforts to prioritize employee wellbeing.

Key Points:

"Partnering with EHE Health will help increase engagement of these critical health services, especially amid the ongoing pandemic.
The new offering complements Danone's existing efforts to advance employee wellbeing, which helps contribute to its best-in-class culture and engaged workforce.
Through the partnership, Danone North America's more than 6,000 employees and their spouses/domestic partners who have chosen Cigna as their health insurance carrier will have access to EHE's newly announced Pulse by EHE Health mobile application.
"We're excited to partner with Danone to provide our premium preventive health services," said Dr. David Levy, MD and Chief Executive Officer of EHE Health.